nanomicellular cyclosporine 0.09% + Lifitegrast
ApprovedUNKNOWN 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Dry Eye
Conditions
Dry Eye
Trial Timeline
Feb 1, 2020 โ Dec 1, 2022
NCT ID
NCT04172961About nanomicellular cyclosporine 0.09% + Lifitegrast
nanomicellular cyclosporine 0.09% + Lifitegrast is a approved stage product being developed by Sun Pharmaceutical for Dry Eye. The current trial status is unknown. This product is registered under clinical trial identifier NCT04172961. Target conditions include Dry Eye.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04172961 | Approved | UNKNOWN |
Competing Products
20 competing products in Dry Eye
Other Products from Sun Pharmaceutical
Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85